Home / Biosimilars

Biosimilars

News

US court rejects Amgen’s bid to block filgrastim biosimilar posted 27/03/2015

On 19 March 2015, the US District Court for North California rejected US biotechnology giant Amgen’s request for a preliminar...

Infliximab biosimilars tighten grip on European markets posted 23/03/2015

The progress of biosimilars onto the European market continues apace with an announcement from Mundipharma that Remsima (infl...

FDA approves its first biosimilar posted 20/03/2015

The US Food and Drug Administration (FDA) announced on 6 March 2015 that it had approved Zarxio (filgrastim-sndz) injection,...

Second Apotex biosimilar under FDA review posted 20/03/2015

Canada-based Apotex announced on 13 February 2015 that the US Food and Drug Administration (FDA) had accepted for filing the...

Hospira launches infliximab biosimilar in major European markets posted 20/03/2015

Injectable generics specialist and biosimilars maker Hospira announced on 16 February 2015 that it was launching its inflixim...

 

Research

Paying physicians to prescribe generics and biosimilars in the US posted 30/03/2015

Healthcare spending on prescription medications comprises 1.6% of gross domestic product (GDP) in the US and continues to ris...

Survey among pharmacists shows high confidence for biosimilar substitution when same generic name is used posted 30/03/2015

Approximately 75% of pharmacists indicated that they would be confident or very confident in substituting an interchangeable...

Equivalent safety and efficacy of nephrology subsequent entry biologics in Canada posted 30/03/2015

A review of efficacy and safety data for subsequent entry biologics (SEBs) used in nephrology practice in Canada has found li...

Comparison of non-originator filgrastim with Neupogen finds no difference in neutropenia recovery periods posted 30/03/2015

Results of an observational study found no difference in Biocad’s non-originator filgrastim (Leucostim) compared to Neupogen...

Generics and off-patent biologicals for cancer treatment in developing countries posted 30/03/2015

The understandable focus on infectious diseases, such as human immunodeficiency virus (HIV), malaria and tuberculosis (TB), h...

 

General

Rheumatologists want to evaluate long-term safety of biosimilars posted 30/03/2015

One of the biggest challenges for biosimilar companies is to convince physicians to use biosimilars instead of their well-kno...

Biosimilars of filgrastim posted 30/03/2015

Filgrastim is a granulocyte colony-stimulating factor (G-CSF). Filgrastim treatment can be used to stimulate the bone marrow...

Biosimilars of darbepoetin alfa posted 30/03/2015

Last update: 20 March 2015Darbepoetin alfa is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red...

Biosimilars of etanercept posted 30/03/2015

Last update: 20 March 2015Etanercept is a biological drug that treats autoimmune diseases by inhibiting tumour necrosis...

Huge discount on biosimilar infliximab in Norway posted 30/03/2015

Norway’s price regulator has been offered a discount of 72% for biosimilar infliximab in the country’s latest tender for drugs.

Generics News Research General

more

Biosimilars News Research General

more